With this software in relapsing-remitting multiple sclerosis, patients can use Bluetooth technology to connect their current autoinjector to the new myBETAapp on their mobile device or computer.
Singapore – Bayer, a German pharmaceutical and life sciences company announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator.
With this software in relapsing-remitting multiple sclerosis, people using the electronic BETACONNECT autoinjector to administer BETASERON (interferon beta-1b) can use Bluetooth technology to connect their current autoinjector to the new myBETAapp on their mobile device or computer. Patients have the opportunity to share their injection data with their BETA Nurse and healthcare team. Viewing this data through the BETACONNECT Navigator may be a useful tool for the health care team to gain insights into patients' injection history and provide support to those taking BETASERON.
"Since introducing the first FDA approved treatment option for relapsing remitting multiple sclerosis patients more than two decades ago, we've listened closely to the community to understand their needs and how we can support them," said Mark Rametta, D.O., FACOI, FACP, Bayer's medical director for Neurology. "The myBETAapp and BETACONNECT Navigator add to the services that we've developed based on patient feedback, including 24/7 access to nurse support and the first and only electronic autoinjector for patients taking BETASERON."
The myBETAapp will be available for free download at the Apple app store, Google Play or Betaseron.com in mid-July.